Brief Summary from IPL Q1’Concall
- Growth in Q1’FY25 is largely driven by volume growth and not the price increase
- During Q1’FY25, formulation growth have been significant while technical growth have been steady
- During this quarter, commissioned the intermediate plant for backward integration for one of herbicide
- Revenue growth of 15-20% expected for FY’25
- Expecting the EBITA margins to reach between 18-20% from Q3’FY25 onwards
- Demand picking up in international markets
- 18-19% revenue from new molecules
- July’24 have been great in terms of business
- From Hamirpur plan, don’t expect revenue during current FY. From FY’26, significant contribution expected from this plant
- 110 Cr. capex required during current year will be funded from internal accruals
- Q1’25 capacity utilization Formulation plant-100%; Technical plan – 66%; The formulation plant capacity will increase in next 1-2 month
- For FY’26, the guidance for revenue growth about 15-20%
- Cash in hands about 140 Cr.
Disc – Invested
| Subscribe To Our Free Newsletter |
